Indolent Lymphoma
From the Journals
Waldenström macroglobulinemia panel advises on IgM paraproteinemic neuropathies
The indications for invasive testing and definitive answers about when and how to treat peripheral neuropathies due to Waldenström...
Conference Coverage
Obinutuzumab vs. rituximab weighed as follicular lymphoma therapy
A broader view indicates rituximab may be preferred depending on a patient’s status and priorities.
Conference Coverage
Phase III trial: VZV protects auto-HCT patients
ORLANDO – An inactivated VZV vaccine for adults undergoing autologous hematopoietic stem cell transplantation has proven safe and effective.
From the Journals
Long view shows doubling of survival in non-Hodgkin lymphoma
The 5-year relative survival rate for non-Hodgkin lymphoma in the United States went from 33% in 1950-1954 to 71.2% in 2008-2013.
From the Journals
Hodgkin lymphoma survival has nearly tripled since the 1950s
Five-year relative survival for Hodgkin lymphoma increased 189% over the approximately 60 years from the early 1950s to 2013.
News from the FDA/CDC
FDA approves ibrutinib for refractory MZL
The Food and Drug Administration has approved ibrutinib for the treatment of patients with relapsed or refractory marginal zone lymphoma, the drug...
Conference Coverage
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
SAN DIEGO – For patients with indolent non-Hodgkin lymphoma, adding rituximab to a standard-combination chemotherapy regimen resulted in...
Conference Coverage
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
SAN DIEGO – Obinutuzumab, a second-generation anti-CD20 antibody touted as the heir apparent to rituximab, offered a PFS edge over rituximab when...
Guidelines
Expert panel offers treatment recommendations in Waldenström macroglobulinemia
News
Triptorelin doesn’t prevent ovarian failure in young women treated for lymphoma
Key clinical point: The GnRH agonist triptorelin failed to prevent chemotherapy-induced premature ovarian failure in young women with lymphoma....
News
Long-term analysis shows dwindling RT benefit for DLBCL
Key clinical point: Long-term observation of clinical trial patients revealed a dwindling of initial survival benefit from radiation added to...